Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Clinical observation on therapeutic efficiency of conprata pulean in the treatment of benign prostate hyperplasia

FU Wei-jun,HE Xue-you,SHI Li-xin,WANG Xi-you,HONG Bao-fa,GAO Jiang-ping,ZHANG Lei,YANG Yong,SHONG Tao(Department of Urology,PLA General Hospital,Beijing 100853,China)  
Objective: To observe the therapeutic effect of the conprata pulean in the treatment of benign prostate hyperplasia.Methods: A total of 80 patients with symptomatic benign prostatic hyperplasia were made a definite diagnosis at outpatient and randomly divided into two groups: 60 patients of treatment group were treated with conprata pulean 3 tablet,po,tid;20 patients in the control group,finateride with 1 tablet,po,qd;All patients received 90 days as a course of treatment.The therapeutic results were assessed before and after the treatment by using following variables:the safety and efficacy of conprata pulean,international prostatic symptom score(IPSS),quality of life(QOL),postvoid residual urine volume(RUV),mean Qmax.Results: The conprata pulean was safe and effective relief for patients with obstructive BPH.The total effective rates was 93.3% in the conprata pulean group.All patients were followed up for 3months in the conprata pulean group.IPSS and QOL was decreased from 14.4±3.8 and 3.1±0.6 to 10.0±2.7 and 1.7±0.6,Qmax increased from 13.2±1.9ml/s to 17.5±4.7ml/s,respectively.There were significant differences of these parameters before and after treatment(P0.05),there was no significent difference between two groups(P0.05).There were no significant differences RUV,prostate volume and PSA.Conclusion: Conprata pulean is an ideal drug in the treatment of BPH patients with obstructive symptom at present.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved